Cephaibols, New Peptaibol Antibiotics with Anthelmintic Properties from Acremonium tubakii DSM 12774.

DOI PubMed 29 References
  • SCHIELL MATTHIAS
    Aventis Pharma Deutschland GmbH, Division Lead Generation, Industriepark Höchst
  • HOFMANN JOACHIM
    Intervet, Industriepark Höchst
  • KURZ MICHAEL
    Aventis Pharma Deutschland GmbH, Division Lead Generation, Industriepark Höchst
  • SCHMIDT FRANK RAINER
    Aventis Pharma Deutschland GmbH, Process Development
  • VÉRIEST LÁSZLÓ
    Aventis Pharma Deutschland GmbH, Division Lead Generation, Industriepark Höchst
  • VOGEL MARTIN
    Aventis Pharma Deutschland GmbH, Global Preclinical Development Analytics
  • WINK JOACHIM
    Aventis Pharma Deutschland GmbH, Division Lead Generation, Industriepark Höchst
  • SEIBERT GERHARD
    Aventis Pharma Deutschland GmbH, Division Lead Generation, Industriepark Höchst

Search this article

Abstract

Two groups of new peptaibol-type antibiotics termed cephaibols have been isolated from the fungus Acremonium tubahii, DSM 12774. These 16- or 17-unit straight-chain peptides, whose structures were characterized by amino acid analyses, 2-D NMR experiments, and by mass spectrometric sequencing, have a high content of the unusual amino acids aminoisobutyric acid and isovaline. The principal constituent of the novel peptaibol mixture is cephaibol A, which is formed in abundance in cultures of the wild strain. The striking biological property of cephaibol A is its pronounced anthelmintic action and activity against ectoparasites.

Journal

References(29)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top